| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Flomoxef sodium targets penicillin-binding proteins (PBPs) in the bacterial cell wall. It acts as a β-lactam inhibitor, binding to PBPs and preventing the transpeptidation step of peptidoglycan synthesis. This leads to the inhibition of cell-wall biosynthesis and bacterial cell death. Its unique structure provides enhanced stability against β-lactamase enzymes, making it useful in resistant infections.
|
|---|---|
| ln Vitro |
In vitro, Flomoxef sodium exhibits good antibacterial effect against a variety of Gram-positive bacteria. It has been shown to be effective against infections caused by Streptococcus pneumoniae, Enterobacter aerogenes, and Acinetobacter baumannii. Its activity can be measured in antibacterial susceptibility assays.
|
| ln Vivo |
In vivo, Flomoxef sodium is used for respiratory infections and bone diseases. It is effective against a variety of infections, including respiratory, urinary tract, and skin infections. Its enhanced stability against β-lactamases makes it useful in treating resistant infections.
|
| Enzyme Assay |
Flomoxef sodium is evaluated in cell-free assays to measure its binding to penicillin-binding proteins. The compound is incubated with PBPs, and the inhibition of transpeptidase activity is measured. Its stability against β-lactamases is assessed using enzymatic assays.
|
| Cell Assay |
Flomoxef sodium is assessed in cell-based antibacterial assays using bacterial cultures. The compound is tested against various bacterial strains, and minimum inhibitory concentrations are determined. Its effects on bacterial growth and viability are evaluated.
|
| Animal Protocol |
Flomoxef sodium is administered parenterally in animal models and in clinical settings. It is used for respiratory, urinary tract, and skin infections. Efficacy is assessed by measuring bacterial clearance and symptom improvement.
|
| ADME/Pharmacokinetics |
Flomoxef sodium has a molecular weight of 457.36 and a molecular formula of C15H16F2N4NaO7S. It has a CAS number of 92823-03-5. The compound is a sodium salt. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Flomoxef sodium beyond its known use as an antibiotic. It is generally well-tolerated but can cause side effects such as allergic reactions. The compound is a therapeutic agent and is available by prescription only.
|
| References | |
| Additional Infomation |
See also: Flomoxef (Note moved to).
Flomoxef sodium is also known as 6315-S. It is a semi-synthetic parenteral oxacephem antibiotic. The compound is a therapeutic agent. |
| Molecular Formula |
C15H17F2N6NAO7S2
|
|---|---|
| Molecular Weight |
518.45
|
| Exact Mass |
518.046
|
| CAS # |
92823-03-5
|
| Related CAS # |
Flomoxef;99665-00-6
|
| PubChem CID |
23679966
|
| Appearance |
White to off-white solid powder
|
| Density |
1.85g/cm3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
33
|
| Complexity |
800
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSC3=NN=NN3CCO)C(=O)[O-])NC(=O)CSC(F)F.[Na+]
|
| InChi Key |
PPPZBOLFWGINKN-YLCXCWDSSA-M
|
| InChi Code |
InChI=1S/C15H18F2N6O7S2.Na/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24;/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27);/q;+1/p-1/t12-,15+;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-7-[[2-(difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~482.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (192.88 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9288 mL | 9.6441 mL | 19.2883 mL | |
| 5 mM | 0.3858 mL | 1.9288 mL | 3.8577 mL | |
| 10 mM | 0.1929 mL | 0.9644 mL | 1.9288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
